• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review.

作者信息

Guillot Mathilde, Rafat Cedric, Buob David, Coppo Paul, Jamme Matthieu, Rondeau Eric, Fain Olivier, Mekinian Arsène

机构信息

AP-HP, Hôpital Saint-Antoine, service de médecine interne and Inflammation-Immunopathology-Biotherapy Department (DHU i2B), Sorbonne Universités, Paris, France.

AP-HP, Hôpital Tenon, service de néphrologie, Sorbonne Universités, Paris, France.

出版信息

Rheumatology (Oxford). 2018 Nov 1;57(11):2055-2057. doi: 10.1093/rheumatology/key228.

DOI:10.1093/rheumatology/key228
PMID:30101319
Abstract
摘要

相似文献

1
Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review.依库珠单抗治疗灾难性抗磷脂综合征——病例报告及文献综述
Rheumatology (Oxford). 2018 Nov 1;57(11):2055-2057. doi: 10.1093/rheumatology/key228.
2
Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature.依库珠单抗治疗难治性灾难性抗磷脂综合征：病例报告及文献系统评价。
Clin Exp Med. 2019 Aug;19(3):281-288. doi: 10.1007/s10238-019-00565-8. Epub 2019 Jun 18.
3
Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab.难治性灾难性抗磷脂综合征患者对依库珠单抗的反应不一致。
Blood. 2020 Nov 19;136(21):2473-2477. doi: 10.1182/blood.2020007499.
4
Eculizumab Induces Sustained Remission in a Patient With Refractory Primary Catastrophic Antiphospholipid Syndrome.依库珠单抗使一名难治性原发性灾难性抗磷脂综合征患者获得持续缓解。
J Clin Rheumatol. 2015 Sep;21(6):311-3. doi: 10.1097/RHU.0000000000000290.
5
Case report: Timing of eculizumab treatment in catastrophic antiphospholipid syndrome.病例报告：卡塔性抗磷脂综合征中依库珠单抗治疗的时机。
Front Immunol. 2024 Sep 10;15:1460317. doi: 10.3389/fimmu.2024.1460317. eCollection 2024.
6
Catastrophic Antiphospholipid Syndrome: Candidate Therapies for a Potentially Lethal Disease.灾难性抗磷脂综合征：一种潜在致命疾病的候选治疗方法。
Annu Rev Med. 2017 Jan 14;68:287-296. doi: 10.1146/annurev-med-042915-102529.
7
Rituximab treatment for resistant antiphospholipid syndrome.利妥昔单抗治疗难治性抗磷脂综合征。
J Rheumatol. 2006 Feb;33(2):355-7.
8
A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor.一例复发性难治性灾难性抗磷脂综合征患者通过使用补体5抑制剂依库珠单抗成功得到治疗。
Rheumatology (Oxford). 2016 Feb;55(2):382-4. doi: 10.1093/rheumatology/kev371. Epub 2015 Oct 15.
9
Thrombotic microangiopathy in the course of catastrophic antiphospholipid syndrome successfully treated with eculizumab: case report and systematic review of the literature.用依库珠单抗成功治疗灾难性抗磷脂综合征过程中的血栓性微血管病：病例报告及文献系统综述
Lupus. 2020 May;29(6):631-639. doi: 10.1177/0961203320917460. Epub 2020 Apr 6.
10
Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis from the "CAPS Registry".依库珠单抗在灾难性抗磷脂综合征（CAPS）中的应用：来自“CAPS 登记处”的描述性分析。
Autoimmun Rev. 2022 Apr;21(4):103055. doi: 10.1016/j.autrev.2022.103055. Epub 2022 Jan 24.

引用本文的文献

1
Novel advances on pathophysiological mechanisms, clinical manifestations, and treatment of antiphospholipid syndrome.抗磷脂综合征的病理生理机制、临床表现及治疗方面的新进展。
Front Immunol. 2025 Aug 21;16:1639065. doi: 10.3389/fimmu.2025.1639065. eCollection 2025.
2
Post-transplant Thrombotic Microangiopathy.移植后血栓性微血管病
J Am Soc Nephrol. 2025 May 1;36(5):940-951. doi: 10.1681/ASN.0000000645. Epub 2025 Jan 31.
3
Case report: Timing of eculizumab treatment in catastrophic antiphospholipid syndrome.病例报告：卡塔性抗磷脂综合征中依库珠单抗治疗的时机。
Front Immunol. 2024 Sep 10;15:1460317. doi: 10.3389/fimmu.2024.1460317. eCollection 2024.
4
Antiphospholipid Patients Admitted in the Intensive Care Unit: What Must The Rheumatologist Know?抗磷脂抗体综合征患者入住重症监护病房：风湿科医生应了解哪些内容？
Curr Rheumatol Rep. 2024 Jul;26(7):269-277. doi: 10.1007/s11926-024-01148-7. Epub 2024 Apr 23.
5
Eculizumab therapy and complement regulation in a case of resistant catastrophic antiphospholipid syndrome.依库珠单抗治疗难治性灾难性抗磷脂综合征及其对补体的调节作用。
BMJ Case Rep. 2024 Mar 5;17(3):e254449. doi: 10.1136/bcr-2022-254449.
6
An update on the biologics for the treatment of antiphospholipid syndrome.抗磷脂综合征治疗的生物制剂最新进展。
Front Immunol. 2023 May 19;14:1145145. doi: 10.3389/fimmu.2023.1145145. eCollection 2023.
7
Emerging Therapies in Antiphospholipid Syndrome.抗磷脂综合征的新兴治疗方法。
Transfus Med Rev. 2022 Oct;36(4):195-203. doi: 10.1016/j.tmrv.2022.09.002. Epub 2022 Sep 24.
8
Acute dilated cardiomyopathy in the setting of catastrophic antiphospholipid syndrome and thrombotic microangiopathy: A case series and review.灾难性抗磷脂综合征和血栓性微血管病背景下的急性扩张型心肌病：病例系列及综述
EJHaem. 2020 Jul 31;1(1):44-50. doi: 10.1002/jha2.71. eCollection 2020 Jul.
9
Eculizumab for refractory thrombosis in antiphospholipid syndrome.依库珠单抗治疗抗磷脂抗体综合征相关难治性血栓
Blood Adv. 2022 Feb 22;6(4):1271-1277. doi: 10.1182/bloodadvances.2021005657.
10
Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?抗磷脂综合征的免疫抑制治疗：是否值得？
Biomedicines. 2021 Feb 1;9(2):132. doi: 10.3390/biomedicines9020132.